Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.
Message: Re: Exactly, "whom" indeed benefits from maintaining the status quo ? eom
3
Aug 07, 2010 01:22PM
5
Aug 07, 2010 02:09PM
And who benefits from the stated objective?:
if that is at the expense or detriment of PTSC, it's Shareholders or it's "legacy", so be it
Definitely NOT all shareholders!
Was the bolded some form of "Statement of Intent"?
.
.
.
Be well
10 Recommendations
Loading...
Loading...
14
Aug 07, 2010 02:22PM
9
Aug 07, 2010 02:38PM
11
Aug 07, 2010 03:52PM
New Message
Please
login
to post a reply